74733-27-0

Basic information

• Product Name: methyl 4-(bromomethyl)-2-methoxybenzoate
• Synonyms: methyl 4-(bromomethyl)-2-methoxybenzoate;2-Methoxy-4-(broMoMethyl)benzoic acid Methyl ester;4-broMoMethyl-2-Methoxy benzoic acid Methyl ester;Methyl 2-Methoxy-4-(bromomethyl)benzoate
• CAS NO: 74733-27-0
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259.09654
• Mol File: 74733-27-0.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 336.1°C at 760 mmHg
• Flash Point: 157.1°C
• Appearance: /
• Density: 1.432g/cm³
• Vapor Pressure: 0.000115mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: methyl 4-(bromomethyl)-2-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(bromomethyl)-2-methoxybenzoate(74733-27-0)
• EPA Substance Registry System: methyl 4-(bromomethyl)-2-methoxybenzoate(74733-27-0)

Safety Data

• Hazardous Substances Data: 74733-27-0(Hazardous Substances Data)

Usage

General Description

Methyl 4-(bromomethyl)-2-methoxybenzoate is a chemical compound that falls under the category of esters and benzene derivatives. It is comprised of a methyl group, a bromomethyl group, and a methoxy group attached to a benzene ring. methyl 4-(bromomethyl)-2-methoxybenzoate is used in organic synthesis and is commonly employed in the pharmaceutical industry for the production of various medications and drugs. Its unique chemical structure makes it useful for the development of new compounds and substances with potential therapeutic properties. However, the compound should be handled and stored with care, as it may pose health and safety hazards if not managed properly. Overall, methyl 4-(bromomethyl)-2-methoxybenzoate plays a critical role in the advancement of pharmaceutical research and development.

InChI:InChI=1/C10H11BrO3/c1-13-9-5-7(6-11)3-4-8(9)10(12)14-2/h3-5H,6H2,1-2H3

Upstream product

• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 50-85-1 2-hydroxy-p-toluic acid 
• 128-08-5 N-Bromosuccinimide 
• 81245-24-1 methyl 4-methyl-2-methoxybenzoate 
• 74-88-4 methyl iodide 
• 704-45-0 2-methoxy-4-methylbenzoic acid 
• 35633-35-3 2-methoxy-4-methylacetophenone 
• 122-46-3 3-acetoxytoluene 
• 6921-64-8 4'-hydroxy-2'-methylacetophenone 
• 67-56-1 methanol 
• 88709-30-2 4-(bromomethyl)-2-methoxybenzoic acid 

Downstream Products

• 92288-31-8 methyl 4-cyanomethyl-2-methoxy-benzoate 
• 55204-14-3 methyl 4-formyl-2-methoxybenzoate 
• 158089-31-7 4-(hydroxymethyl)-2-methoxybenzoic acid 
• 251478-89-4 2-methoxy-4-[5'-(8-phenyl-octylcarbamoyl)-3,3-bis-trifluoromethyl-[1,1':3'1]terphenyl-2'yloxymethyl]-benzoic acid methyl ester 
• 1351169-42-0 methyl 2-(3-{2-[2-(2-{2-[(S)-2-((2S,3R)-3-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-2-hydroxy-4-phenylbutanamido)-4-methylpentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-27-1 2-[3-(2-{2-[2-(2-{(S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanamido}ethoxy)ethoxy]ethoxy}acetamido)propoxy]-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid 
• 1351169-43-1 (S,E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoate 
• 1351169-28-2 (S,E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoic acid 
• 1351169-33-9 C₂₆H₃₂O₄ 
• 1351169-34-0 C₂₅H₃₁BrO₄ 
• 1351169-35-1 (E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-hydroxybenzoate 
• 1351169-36-2 (E)-methyl 2-[3-(tert-butoxycarbonylamino)propoxy]-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-37-3 (E)-methyl 2-(3-aminopropoxy)-4-[3-(3,5-di-tertbutylphenyl)-3-oxoprop-1-enyl]benzoate hydrochloride 
• 189094-76-6 methyl 4-[(acetyloxy)methyl]-2-methoxybenzoate 

Relevant articles and documents

Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors

A series of macrocyclic analogues were designed and synthesized based on the cocrystal structure of small molecule plasma kallikrein (pKal) inhibitor, 2, with the pKal protease domain. This led to the discovery of a potent macrocyclic pKal inhibitor 29, w

A pharmaceutical composition containing 2-hydroxy-7-methyl octahydrophenanthrene derivative as an estrogen receptor ligand or a pharmaceutically acceptable salt thereof as an effective component

Provided are a compound represented by chemical formulas I and II, or a pharmaceutically acceptable ester, amide, or carbamate salt thereof; and a solvent compound comprising a solvent compound of the ester, amide, or carbamate salt thereof. In addition, provided are use of the compound in treating or preventing diseases or disorders related to activation of an estrogen receptor, and a pharmaceutical composition comprising the compound. In chemical formulas I and II, definitions of R_1, R_2, R_3, and R_4 are the same as those in the specification.COPYRIGHT KIPO 2016

Mild Benzylic Monobromination of Methyl Toluates in Aqueous CTAB

A strategy has been developed for the regioselective monobromination of methyl toluates by using tert-butylhydrogen peroxide and potassium bromide (TBHP/KBr) in a cetyltrimethylammonium bromide (CTAB) micellar medium. Ultrasonic and microwave-assisted protocols recorded increased rates and product yields under mild reaction conditions, coupled with a straightforward isolation procedure.